Evaluation of antibody-bearing liposomal amphotericin B in the treatment of systemic candidiasis in a neutropenic murine model
- 1 January 1991
- journal article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 29 (6) , 419-421
- https://doi.org/10.1080/02681219180000671
Abstract
The efficacy of liposomal amphotericin B bearing anticandidal antibodies (LAMB-Ab) was investigated in the treatment of systemic candidiasis in a murine model made neutropenic by an intraperitoneal injection of cyclophosphamide. Treatment with a single dose (0.6 mg amphotericin B kg-1 body weight) of LAMB-Ab resulted in an improved survival of neutropenic mice infected with Candida albicans compared to neutropenic mice treated with identical doses of liposomal amphotericin B or free amphotericin B.Keywords
This publication has 4 references indexed in Scilit:
- Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasisAntimicrobial Agents and Chemotherapy, 1989
- Life‐Threatening Opportunistic Fungal Infection in Patients with the Acquired Immunodeficiency SyndromeAnnals of the New York Academy of Sciences, 1988
- Fungal Infections in Cancer PatientsAnnals of the New York Academy of Sciences, 1988
- Development of amphotericin B liposomes bearing antibody specific to Candida albicansMycopathologia, 1988